Importer of Controlled Substances Application: VHG Labs DBA LGC Standards, 29546-29547 [2019-13377]
Download as PDF
<![CDATA[
29546
Federal Register / Vol. 84, No. 121 / Monday, June 24, 2019 / Notices
jbell on DSK3GLQ082PROD with NOTICES
Amazon.com, Inc., 410 Terry Avenue
North, Seattle, WA 98109.
Dell Technologies Inc., One Dell Way,
Round Rock, TX 78682.
HP Inc., 1501 Page Mill Road, Palo Alto,
CA 94304.
Lenovo Group Ltd., 6 Chuang ye Road,
Haidian District, Beijing 100085
China.
Levono (United States) Inc., 1009 Think
Place, Building One, Morrisville, NC
27560.
Microsoft Corporation, One Microsoft
Way, Redmond, WA 98052.
Motorola Mobility LLC, 222 W.
Merchandise Mart Plaza, Suite 1800,
Chicago, IL 60654.
Samsung Electronics Co., Ltd., 129
Samsung-Ro, Maetab-3dong,
Yeongtong-gu, Suwon, 443–742 South
Korea.
Samsung Electronics America, Inc., 85
Challenger Rd., Ridgefield Park, NJ
07660.
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
The Office of Unfair Import
Investigations will not be named as a
party to this investigation.
Responses to the amended complaint
and the notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the amended complaint
and the notice of investigation.
Extensions of time for submitting
responses to the amended complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a respondent to file a timely
response to each allegation in the
amended complaint and in this notice
may be deemed to constitute a waiver of
the right to appear and contest the
allegations of the amended complaint
and this notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the amended complaint and
this notice and to enter an initial
determination and a final determination
containing such findings, and may
result in the issuance of an exclusion
order or a cease and desist order or both
directed against the respondent.
By order of the Commission.
VerDate Sep<11>2014
16:50 Jun 21, 2019
Jkt 247001
Issued: June 19, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019–13379 Filed 6–21–19; 8:45 am]
BILLING CODE 7020–02–P
JOINT BOARD FOR THE
ENROLLMENT OF ACTUARIES
Meeting of the Advisory Committee;
Meeting
Joint Board for the Enrollment
of Actuaries.
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:
The Joint Board for the
Enrollment of Actuaries gives notice of
a meeting of the Advisory Committee on
Actuarial Examinations (portions of
which will be open to the public) at the
Internal Revenue Service, 1111
Constitution Avenue NW, Washington,
DC, on July 11 and 12, 2019.
DATES: Thursday, July 11, 2019, from
9:00 a.m. to 5:00 p.m., and Friday, July
12, 2019, from 8:30 a.m. to 5:00 p.m.
ADDRESSES: The meeting will be held at
the Internal Revenue Service; 1111
Constitution Avenue NW; Washington,
DC 20224.
FOR FURTHER INFORMATION CONTACT: Ms.
Elizabeth Van Osten, Designated Federal
Officer, Advisory Committee on
Actuarial Examinations, (202) 317–
3648.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Advisory
Committee on Actuarial Examinations
will meet at the Internal Revenue
Service; 1111 Constitution Avenue NW;
Washington, DC 20224, on Thursday,
July 11, 2019, from 9:00 a.m. to 5:00
p.m., and Friday, July 12, 2019, from
8:30 a.m. to 5:00 p.m.
The purpose of the meeting is to
discuss topics and questions that may
be recommended for inclusion on future
Joint Board examinations in actuarial
mathematics and methodology referred
to in 29 U.S.C. 1242(a)(1)(B) and to
review the May 2019 Pension (EA–2L)
and Basic (EA–1) Examinations in order
to make recommendations relative
thereto, including the minimum
acceptable pass scores. Topics for
inclusion on the syllabus for the Joint
Board’s examination program for the
November 2019 Pension (EA–2F)
Examination will be discussed.
A determination has been made as
required by section 10(d) of the Federal
Advisory Committee Act, 5 U.S.C. App.,
that the portions of the meeting dealing
with the discussion of questions that
may appear on the Joint Board’s
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
examinations and the review of the May
2019 EA–2L and EA–1 Examinations
fall within the exceptions to the open
meeting requirement set forth in 5
U.S.C. 552b(c)(9)(B), and that the public
interest requires that such portions be
closed to public participation.
The portion of the meeting dealing
with the discussion of the other topics
will commence at 1:00 p.m. on July 11,
2019, and will continue for as long as
necessary to complete the discussion,
but not beyond 3:00 p.m. Time
permitting, after the close of this
discussion by Committee members,
interested persons may make statements
germane to this subject. Persons wishing
to make oral statements should notify
the Joint Board in writing prior to the
meeting in order to aid in scheduling
the time available and should submit
the written text, or at a minimum, an
outline of comments they propose to
make orally. Such comments will be
limited to 10 minutes in length. All
persons planning to attend the public
session should notify the Joint Board in
writing to obtain building entry.
Notifications of intent to make an oral
statement or to attend must be sent
electronically, by no later than July 3,
2019, to NHQJBEA@irs.gov. In addition,
any interested person may file a written
statement for consideration by the Joint
Board and the Committee by sending it
to: Ms. Elizabeth Van Osten; Joint Board
for the Enrollment of Actuaries; SE:RPO,
Room 3422; 1111 Constitution Avenue
NW, Washington, DC 20224.
Dated: June 18, 2019.
Thomas V. Curtin, Jr.,
Executive Director, Joint Board for the
Enrollment of Actuaries.
[FR Doc. 2019–13365 Filed 6–21–19; 8:45 am]
BILLING CODE 4830–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: VHG Labs DBA LGC
Standards
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 24, 2019. Such persons
may also file a written request for a
hearing on the application on or before
July 24, 2019.
DATES:
E:\FR\FM\24JNN1.SGM
24JNN1
29547
Federal Register / Vol. 84, No. 121 / Monday, June 24, 2019 / Notices
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
ADDRESSES:
Morrissette Drive, Springfield, Virginia
22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on March 6, 2019, VHG
SUPPLEMENTARY INFORMATION:
Labs DBA LGC Standards, 3 Perimeter
Road, Manchester, New Hampshire
03103 applied to be registered as an
importer of the following basic classes
of controlled substances:
Controlled substance
Drug code
jbell on DSK3GLQ082PROD with NOTICES
Cathinone ...................................................................................................................................................................
Methcathinone ............................................................................................................................................................
Naphyrone ..................................................................................................................................................................
N-Ethylamphetamine ..................................................................................................................................................
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ..............................................................................................
SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ...........................................
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .........................................................
JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthoyl)indole) ..............................................................................................
SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl]indole ................................................................
JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ........................................................................
JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .................................................................................................
UR–144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ...........................................................
JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) .................................................................................................
Ibogaine ......................................................................................................................................................................
Lysergic acid diethylamide .........................................................................................................................................
Marihuana ..................................................................................................................................................................
Mescaline ...................................................................................................................................................................
3,4-Methylenedioxymethamphetamine ......................................................................................................................
5-Methoxy-N-N-dimethyltryptamine ............................................................................................................................
Psilocyn ......................................................................................................................................................................
4-Methyl-alphapyrrolidinopropiophenone (4-MePPP) ................................................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) .................................................................................................
Butylone .....................................................................................................................................................................
Pentylone ...................................................................................................................................................................
Codeine-N-oxide ........................................................................................................................................................
Desomorphine ............................................................................................................................................................
Dihydromorphine ........................................................................................................................................................
Heroin .........................................................................................................................................................................
Morphine-N-oxide .......................................................................................................................................................
Normorphine ...............................................................................................................................................................
Tilidine ........................................................................................................................................................................
Alpha-methylfentanyl ..................................................................................................................................................
Methamphetamine ......................................................................................................................................................
Phenmetrazine ...........................................................................................................................................................
Amobarbital ................................................................................................................................................................
Pentobarbital ..............................................................................................................................................................
Secobarbital ...............................................................................................................................................................
Glutethimide ...............................................................................................................................................................
Phencyclidine .............................................................................................................................................................
Phenylacetone ............................................................................................................................................................
Dihydrocodeine ..........................................................................................................................................................
Diphenoxylate .............................................................................................................................................................
Ecgonine ....................................................................................................................................................................
Ethylmorphine ............................................................................................................................................................
Levorphanol ................................................................................................................................................................
Meperidine ..................................................................................................................................................................
Meperidine intermediate-B .........................................................................................................................................
Meperidine intermediate-C .........................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ........................................................................................................
14-Hydroxmorphone ...................................................................................................................................................
Noroxymorphone ........................................................................................................................................................
Sufentanil ...................................................................................................................................................................
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes. Placement of
these drug codes onto the company’s
registration does not translate into
automatic approval of subsequent
permit applications to import controlled
substances. Approval of permit
applications will occur only when the
registrant’s business activity is
VerDate Sep<11>2014
16:50 Jun 21, 2019
Jkt 247001
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non- approved finished
dosage forms for commercial sale.
Dated: June 6, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–13377 Filed 6–21–19; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
1235
1237
1258
1475
6250
7008
7048
7081
7104
7118
7122
7144
7203
7260
7315
7360
7381
7405
7431
7438
7498
7540
7541
7542
9053
9055
9145
9200
9307
9313
9750
9814
1105
1631
2125
2270
2315
2550
7471
8501
9120
9170
9180
9190
9220
9230
9233
9234
9273
9665
9668
9740
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
Notice of Extension of Comment
Period of Proposed Consent Decree
Under the Clean Water Act
On May 17, 2019, the Department of
Justice lodged a proposed consent
decree with the United States District
Court for the Western District of
Washington in the lawsuit entitled
E:\FR\FM\24JNN1.SGM
24JNN1
]]>Agencies
[Federal Register Volume 84, Number 121 (Monday, June 24, 2019)]
[Notices]
[Pages 29546-29547]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-13377]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: VHG Labs DBA LGC
Standards
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before July 24, 2019. Such
persons may also file a written request for a hearing on the
application on or before July 24, 2019.
[[Page 29547]]
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on March 6, 2019, VHG Labs DBA LGC Standards, 3
Perimeter Road, Manchester, New Hampshire 03103 applied to be
registered as an importer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Cathinone........................ 1235 I
Methcathinone.................... 1237 I
Naphyrone........................ 1258 I
N-Ethylamphetamine............... 1475 I
JWH-250 (1-Pentyl-3-(2- 6250 I
methoxyphenylacetyl)indole).
SR-18 (Also known as RCS-8) (1- 7008 I
Cyclohexylethyl-3-(2-
methoxyphenylacetyl)indole).
APINACA and AKB48 N-(1-Adamantyl)- 7048 I
1-pentyl-1H-indazole-3-
carboxamide.
JWH-081 (1-Pentyl-3-(1-(4- 7081 I
methoxynaphthoyl)indole).
SR-19 (Also known as RCS-4) (1- 7104 I
Pentyl-3-[(4-methoxy)-
benzoyl]indole.
JWH-018 (also known as AM678) (1- 7118 I
Pentyl-3-(1-naphthoyl)indole).
JWH-122 (1-Pentyl-3-(4-methyl-1- 7122 I
naphthoyl)indole).
UR-144 (1-Pentyl-1H-indol-3- 7144 I
yl)(2,2,3,3-
tetramethylcyclopropyl)methanone.
JWH-203 (1-Pentyl-3-(2- 7203 I
chlorophenylacetyl)indole).
Ibogaine......................... 7260 I
Lysergic acid diethylamide....... 7315 I
Marihuana........................ 7360 I
Mescaline........................ 7381 I
3,4-Methylenedioxymethamphetamine 7405 I
5-Methoxy-N-N-dimethyltryptamine. 7431 I
Psilocyn......................... 7438 I
4-Methyl- 7498 I
alphapyrrolidinopropiophenone (4-
MePPP).
Methylone (3,4-Methylenedioxy-N- 7540 I
methylcathinone).
Butylone......................... 7541 I
Pentylone........................ 7542 I
Codeine-N-oxide.................. 9053 I
Desomorphine..................... 9055 I
Dihydromorphine.................. 9145 I
Heroin........................... 9200 I
Morphine-N-oxide................. 9307 I
Normorphine...................... 9313 I
Tilidine......................... 9750 I
Alpha-methylfentanyl............. 9814 I
Methamphetamine.................. 1105 II
Phenmetrazine.................... 1631 II
Amobarbital...................... 2125 II
Pentobarbital.................... 2270 II
Secobarbital..................... 2315 II
Glutethimide..................... 2550 II
Phencyclidine.................... 7471 II
Phenylacetone.................... 8501 II
Dihydrocodeine................... 9120 II
Diphenoxylate.................... 9170 II
Ecgonine......................... 9180 II
Ethylmorphine.................... 9190 II
Levorphanol...................... 9220 II
Meperidine....................... 9230 II
Meperidine intermediate-B........ 9233 II
Meperidine intermediate-C........ 9234 II
Dextropropoxyphene, bulk (non- 9273 II
dosage forms).
14-Hydroxmorphone................ 9665 II
Noroxymorphone................... 9668 II
Sufentanil....................... 9740 II
------------------------------------------------------------------------
The company plans to import analytical reference standards for
distribution to its customers for research and analytical purposes.
Placement of these drug codes onto the company's registration does not
translate into automatic approval of subsequent permit applications to
import controlled substances. Approval of permit applications will
occur only when the registrant's business activity is consistent with
what is authorized under 21 U.S.C. 952(a)(2). Authorization will not
extend to the import of FDA approved or non- approved finished dosage
forms for commercial sale.
Dated: June 6, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-13377 Filed 6-21-19; 8:45 am]
BILLING CODE 4410-09-P
